Relmada Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:RLMD Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
15 Dec 25	BuyUS$48,060	Maged Shenouda	Individual	11,665	US$4.12
15 Dec 25	BuyUS$113,300	Sergio Traversa	Individual	27,500	US$4.12
05 Nov 25	BuyUS$1,100,000	Maged Shenouda	Individual	500,000	US$2.20
05 Nov 25	BuyUS$599,500	Sergio Traversa	Individual	272,500	US$2.20
05 Nov 25	BuyUS$299,200	Charles Ence	Individual	136,000	US$2.20
05 Nov 25	BuyUS$198,000	Paul Kelly	Individual	90,000	US$2.20
28 Aug 25	BuyUS$178,095	Sergio Traversa	Individual	265,976	US$0.74
20 May 25	BuyUS$174,713	Sergio Traversa	Individual	350,000	US$0.56
20 May 25	BuyUS$97,208	Maged Shenouda	Individual	200,000	US$0.52
16 May 25	BuyUS$103,330	Charles Ence	Individual	228,961	US$0.45
16 May 25	BuyUS$86,060	Paul Kelly	Individual	200,000	US$0.43

Insider Trading Volume

Insider Buying: RLMD insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RLMD?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	3,017,420	4.11%
Individual Insiders	4,906,156	6.69%
Institutions	12,783,073	17.4%
General Public	52,626,973	71.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 143%.

Top Shareholders

Top 25 shareholders own 27.44% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
4.83%	Ikarian Capital, LLC	3,543,359	US$15.5m	8,700%	2.47%
4.5%	Squadron Capital Management Llc	3,298,500	US$14.4m	0%	no data
4.11%	Trigone Pharma Ltd.	3,017,420	US$13.2m	0%	no data
2.59%	Kevin Kotler	1,899,930	US$8.3m	0%	no data
1.77%	Sergio Traversa	1,300,000	US$5.7m	30%	no data
1.09%	Maged Shenouda	800,000	US$3.5m	177%	no data
1.01%	Driehaus Capital Management LLC	740,006	US$3.2m	0%	0.02%
0.95%	Boothbay Fund Management, LLC	693,236	US$3.0m	0%	0.08%
0.79%	Acadian Asset Management LLC	582,543	US$2.5m	-5.96%	no data
0.69%	BlackRock, Inc.	508,000	US$2.2m	0%	no data
0.68%	Paul Kelly	502,295	US$2.2m	21.8%	no data
0.57%	The Vanguard Group, Inc.	418,580	US$1.8m	15%	no data
0.55%	Charles Ence	403,931	US$1.8m	50.8%	no data
0.55%	AdvisorShares Investments, LLC	403,488	US$1.8m	1.76%	0.17%
0.4%	Geode Capital Management, LLC	296,215	US$1.3m	-2.03%	no data
0.37%	Marshall Wace LLP	272,053	US$1.2m	76%	no data
0.31%	Deutsche Asset & Wealth Management	224,846	US$982.6k	0%	no data
0.28%	Corient Private Wealth LLC	206,667	US$903.1k	0%	no data
0.24%	Two Sigma Investments, LP	173,614	US$758.7k	82%	no data
0.23%	Renaissance Technologies LLC	169,700	US$741.6k	13.1%	no data
0.22%	Parsons Capital Management, Inc.	163,336	US$713.8k	0%	0.04%
0.22%	RBF Capital LLC	163,261	US$713.5k	0%	0.03%
0.19%	Susquehanna International Group, LLP	138,424	US$604.9k	110%	no data
0.14%	State Street Global Advisors, Inc.	101,820	US$444.9k	-4.6%	no data
0.14%	MGO One Seven LLC	100,000	US$437.0k	0%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/04 15:49
End of Day Share Price	2026/01/02 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Relmada Therapeutics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Maxim Jacobs	Edison Investment Research
Farzin Haque	Jefferies LLC
Andrew Tsai	Jefferies LLC